Overview

Evidence-based recommendations on casirivimab plus imdevimab (Ronapreve), nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

The government, the NHS or the UK Health Security Agency may choose to use these treatments in a different way from that recommended in this guidance in exceptional circumstances such as:

  • the widespread incidence of variants of COVID-19 to which the general population has no natural or vaccine immunity
  • local or national high rates of hospitalisation with COVID-19.

In June 2023, we added a section with supporting information on risk factors for progression to severe COVID-19. This supporting information was provided by the independent advisory group commissioned by the Department of Health and Social Care.

Commercial arrangements

There are simple discount patient access schemes for sotrovimab and tocilizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact the following for details:

Guidance development process

How we develop NICE technology appraisal guidance

This guidance does not cover molnupiravir, remdesivir or tixagevimab plus cilgavimab for treating COVID-19. NICE plans to publish technology appraisal guidance on these treatments in the future. For more information, see NICE's development page on molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19.

This guidance updates recommendations on casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab in the therapeutics section of NICE’s rapid guideline on managing COVID-19, which contains all our latest recommendations.

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)